MetLife Posts Record 3Q Adjusted EPS of $2.85, Beats VII and Expense Targets
MET sits 56% above its 52-week low of $67.33.
Summary
MetLife reported record 3Q26 adjusted EPS of $2.85 excluding notable items, up 22%, with variable investment income of $720 million pre-tax well above the ~$400 million quarterly guidance and a 11.9% direct expense ratio ahead of the 12.1% annual target.
Key Events · Earnings and Guidance · MET
-
Record 3Q Adjusted EPS of $2.85
Adjusted earnings excluding total notable items rose 17% to $1,826 million, or $2.85 per share, up 22% year over year — the highest quarterly adjusted EPS in MetLife's history. Net income was $2,351 million, or $3.67 per share, up 187%.
-
VII and Expense Ratio Beat Targets
Variable investment income was $720 million pre-tax versus roughly $400 million quarterly guidance, and the direct expense ratio excluding notable items and PRT came in at 11.9% against a 12.1% full-year target. Adjusted ROE excluding notable items was 19.6%, above the 15-17% annual target.
-
Actuarial Review a $46M Drag
The annual global actuarial assumption review reduced adjusted earnings by $46 million and net income by $56 million, driven by a $65 million unfavorable RIS impact from lower mortality, partly offset by a $52 million favorable Asia adjustment.
-
~$1B Returned, Buyback on Pace
MetLife returned roughly $1.0 billion to shareholders in 3Q26 through $380 million of common dividends and $650 million of buybacks. Year-to-date repurchases reached $2.4 billion through October, including $265 million in October 2026, against the previously authorized $3 billion program.
Analysis · MET · Finance
MetLife's third quarter was its best ever on an adjusted basis: $2.85 per share excluding notable items, up 22%, with revenue growth in all six segments. Against management's own targets, the two numbers that matter most both came in ahead — variable investment income of $720 million pre-tax versus roughly $400 million quarterly guidance, and a 11.9% direct expense ratio versus a 12.1% full-year target. The annual actuarial review was a modest $46 million drag on adjusted earnings, concentrated in RIS on lower mortality. Capital return stayed on pace at about $1 billion for the quarter, and holding company cash of $3.4 billion sits inside the $3.0-4.0 billion buffer. Because the headline EPS figures were already circulating this evening, the incremental information is in the segment detail and the target-beating metrics.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MET was trading at $104.92 on NYSE in the Finance sector, with a market capitalization of approximately $65.4B. The 52-week trading range was $67.33 to $103.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.